Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2016-03-17 07:01 |
CP en français
|
French | 374.1 KB | ||
| 2016-03-17 07:01 |
PR in English
|
English | 371.8 KB | ||
| 2016-02-18 07:01 |
FY results 2015
|
English | 195.9 KB | ||
| 2016-02-18 07:01 |
Résultats annuels 2015
|
French | 202.3 KB | ||
| 2016-02-08 07:01 |
Start of Phase I trial of monalizumab in combination with durvalumab
|
English | 82.1 KB | ||
| 2016-02-08 07:01 |
Démarrage de l'essai de Phase I monalizumab avec durvalumab
|
French | 85.0 KB | ||
| 2016-02-05 07:00 |
Number of shares and voting rights of Innate Pharma as at Feb 3, 2016
|
English | 30.0 KB | ||
| 2016-02-05 07:00 |
Nombre d'actions et droits de vote d'Innate Pharma au 03/02/16
|
French | 29.6 KB | ||
| 2016-01-11 03:00 |
Sanofi et Innate Pharma collaborent ...
|
French | 54.5 KB | ||
| 2016-01-10 22:30 |
Innate Pharma in-licenses OREGA biotech's anti-CD39 program
|
English | 156.7 KB | ||
| 2016-01-10 22:30 |
Innate Pharma acquiert le programme d'anticorps inhibiteurs de CD39
|
French | 159.9 KB | ||
| 2016-01-09 07:00 |
Number of shares and voting rights as at January 6, 2016
|
English | 66.6 KB | ||
| 2016-01-09 07:00 |
Nombre d’actions et de droits de vote au 6 janvier 2016
|
French | 67.9 KB | ||
| 2016-01-08 19:20 |
Bilan annuel du contrat de liquidité
|
French | 149.1 KB | ||
| 2016-01-08 19:20 |
FULL-YEAR REPORT ON INNATE PHARMA'S LIQUIDITY CONTRACT
|
English | 150.9 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
